Senti Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.62
- Today's High:
- $0.67
- Open Price:
- $0.62
- 52W Low:
- $0.59
- 52W High:
- $8.77
- Prev. Close:
- $0.638
- Volume:
- 15357
Company Statistics
- Market Cap.:
- $30.01 million
- Book Value:
- 2.191
- Revenue TTM:
- $4.05 million
- Operating Margin TTM:
- -1892.02%
- Gross Profit TTM:
- $-29781000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.66%
- Return on Equity TTM:
- -57.43%
Company Profile
Senti Biosciences Inc had its IPO on 2022-06-09 under the ticker symbol SNTI.
The company operates in the Healthcare sector and Biotechnology industry. Senti Biosciences Inc has a staff strength of 122 employees.
Stock update
Shares of Senti Biosciences Inc opened at $0.62 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.62 - $0.67, and closed at $0.64.
This is a -0.08% slip from the previous day's closing price.
A total volume of 15,357 shares were traded at the close of the day’s session.
In the last one week, shares of Senti Biosciences Inc have slipped by -5.42%.
Senti Biosciences Inc's Key Ratios
Senti Biosciences Inc has a market cap of $30.01 million, indicating a price to book ratio of 0.4344 and a price to sales ratio of 13.2794.
In the last 12-months Senti Biosciences Inc’s revenue was $4.05 million with a gross profit of $-29781000 and an EBITDA of $-74463000. The EBITDA ratio measures Senti Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Senti Biosciences Inc’s operating margin was -1892.02% while its return on assets stood at -27.66% with a return of equity of -57.43%.
In Q2, Senti Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 31%.
Senti Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Senti Biosciences Inc’s profitability.
Senti Biosciences Inc stock is trading at a EV to sales ratio of 1.8178 and a EV to EBITDA ratio of 0.3459. Its price to sales ratio in the trailing 12-months stood at 13.2794.
Senti Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $143.63 million
- Total Liabilities
- $10.43 million
- Operating Cash Flow
- $18.33 million
- Capital Expenditure
- $3.67 million
- Dividend Payout Ratio
- 0%
Senti Biosciences Inc ended 2024 with $143.63 million in total assets and $0 in total liabilities. Its intangible assets were valued at $143.63 million while shareholder equity stood at $97.42 million.
Senti Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $10.43 million in other current liabilities, 4000.00 in common stock, $-210705000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $36.75 million and cash and short-term investments were $59.64 million. The company’s total short-term debt was $2,551,000 while long-term debt stood at $0.
Senti Biosciences Inc’s total current assets stands at $63.49 million while long-term investments were $0 and short-term investments were $22.88 million. Its net receivables were $567000.00 compared to accounts payable of $2.59 million and inventory worth $3.15 million.
In 2024, Senti Biosciences Inc's operating cash flow was $18.33 million while its capital expenditure stood at $3.67 million.
Comparatively, Senti Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.64
- 52-Week High
- $8.77
- 52-Week Low
- $0.59
- Analyst Target Price
- $4
Senti Biosciences Inc stock is currently trading at $0.64 per share. It touched a 52-week high of $8.77 and a 52-week low of $8.77. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $0.74 and 200-day moving average was $1.2 The short ratio stood at 5.36 indicating a short percent outstanding of 0%.
Around 2780.1% of the company’s stock are held by insiders while 2843.6% are held by institutions.
Frequently Asked Questions About Senti Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.